Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 19/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13620236 | 0.91 | PIM1 (0.42) | DDR1PIM1FLT3KCNH2PIM3 | |
| SCHEMBL13620277 | 0.89 | PIM1 (0.42) | PIM1FLT3KCNH2PIM3PIM2 | |
| SCHEMBL13608271 | 0.87 | CCNT1 (0.39) | DDR1 | |
| SCHEMBL13620267 | 0.85 | DDR1 (0.40) | DDR1PIM1 | |
| SCHEMBL13620232 | 0.80 | KDM4E (0.38) | PIM1FLT3KCNH2PIM3PIM2 | |
| SCHEMBL13620505 | 0.80 | ADORA2A (0.41) | PIM1FLT3KCNH2PIM3PIM2 | |
| SCHEMBL13620507 | 0.79 | PIM1 (0.38) | DDR1PIM1FLT3KCNH2PIM3 | |
| SCHEMBL13620423 | 0.79 | USP1 (0.38) | DDR1 | |
| SCHEMBL13620230 | 0.79 | BRD4 (0.37) | DDR1PIM1FLT3KCNH2PIM3 | |
| SCHEMBL3848468 | 0.79 | MCHR1 (0.42) | DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | DDR1 3201/4885PIM1 596/4885FLT3 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.